Patient-Controlled Subcutaneous Analgesia with Hydromorphone versus Oral Oxycontin for Opioid Titration of Cancer Pain: A Prospective Multicenter Randomized Trial
Xiaoguang Xiao,Jianhai Sun,Dongsheng Zhang,Linjun Li,Haibo Zhou,Yongjun Li,Quan Li,Zhongshi He,Yang Fu,Qiwen Duan,Guping Zheng,Ze Tang,Qian Chu,Yuan Chen
DOI: https://doi.org/10.2147/jpr.s451698
IF: 2.8319
2024-04-12
Journal of Pain Research
Abstract:Xiaoguang Xiao, 1 Jianhai Sun, 2 Dongsheng Zhang, 3 Linjun Li, 4 Haibo Zhou, 5 Yongjun Li, 6 Quan Li, 7 Zhongshi He, 8 Yang Fu, 9 Qiwen Duan, 10 Guping Zheng, 11 Ze Tang, 12 Qian Chu, 1, &ast Yuan Chen 1, &ast 1 Department of Oncology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Department of Oncology, Hubei Zhongshan Hospital, Wuhan, Hubei, People's Republic of China; 3 Department of Oncology, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei, People's Republic of China; 4 Department of Oncology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, Hubei, People's Republic of China; 5 Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei, People's Republic of China; 6 Department of Oncology, Yichang Second People's Hospital, Yichang, Hubei, People's Republic of China; 7 Department of Oncology, Xiangyang Central Hospital, Xiangyang, Hubei, People's Republic of China; 8 Department of Oncology, Xiangyang No 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, People's Republic of China; 9 Department of Oncology, Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, People's Republic of China; 10 Department of Oncology, Taihe Hospital, Shiyan, Hubei, People's Republic of China; 11 Department of Oncology, Xiaogan Central Hospital, Xiaogan, Hubei, People's Republic of China; 12 Department of Oncology, Huangshi Central Hospital, Huangshi, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qian Chu; Yuan Chen, Email ; Background: Studies have shown that oral oxycontin tablets can be used for opioid titration. The European Society for Medical Oncology (ESMO) guidelines for adult cancer pain recommend opioid titration through the parenteral route, usually the intravenous or subcutaneous route. Patient-controlled subcutaneous analgesia (PCSA) with hydromorphone needs further evaluation for opioid titration. This prospective multicenter study was designed to compare the efficacy and safety of hydromorphone PCSA with oral oxycontin tablets for opioid titration of cancer pain. Patients and Methods: Eligible patients with cancer pain were randomly assigned in a 1:1 ratio to the PCSA group or the oxycontin group for dose titration. Different titration methods were given in both groups depending on whether the patient had an opioid tolerance. The primary endpoint of this study was time to successful titration (TST). Results: A total of 256 patients completed this study. The PCSA group had a significantly lower TST compared with the oxycontin group (median [95% confidence interval (CI)], 5.5[95% CI:2.5– 11.5] hours vs.16.0 [95% CI:11.5– 22.5] hours; p < 0.001). The frequency (median; interquartile) of breakthrough pain (Btp) over 24 hours was significantly lower in the PCSA group (2.5;2.0– 3.5) than in the oxycontin group.(3.0; 2.5– 4.5) ( p =0.04). The pain was evaluated by numeric rating scale (NRS) score at 12 hours after the start of titration. The pain score (median; interquartile) was significantly lower in the PCSA versus the oxycontin group (2.5;1.5– 3.0) vs 4.5;3.0– 6.0) ( p =0.02). The equivalent dose of oral morphine (EDOM) for a successful titration was similar in both groups ( p =0.29), but there was a significant improvement in quality of life (QoL) in both groups ( p =0.03). No between-group difference in the incidence of opioid-related adverse effects was observed ( p =0.32). Conclusion: Compared with oral oxycontin tablet, the use of PCSA with hydromorphone achieved a shorter titration duration for patients with cancer pain ( p < 0.001), without significantly increasing adverse events ( p =0.32). Keywords: cancer pain, opioid titration, oxycontin tablets, hydromorphone, patient-controlled subcutaneous analgesia Pain is the most common clinical symptom in patients with cancer. 1 Cancer-related pain is the most important factor affecting cancer patients' quality of life. 2 However, effective and fast-onset treatment for cancer pain is still lacking. 3–5 Determining the ideal therapeutic opioid dose is the key to successfully controlling cancer pain. The purpose of dose titration is to provide quick and satisfactory pain control, to determine a reasonable therapeutic dose timely, and to avoid side -Abstract Truncated-
clinical neurology